A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513708-33-00

Acronym

STRO-002-GM2

Enrollment

Registered

2024-11-04

Start date

2022-11-23

Completion date

2025-07-16

Last updated

2024-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026